Ouch, what's the bottom here u think.. |
vaston. Grow up. |
SYME IS NOW READY TO FLY |
Continues to disappoint. |
Dounbtless if profits halved market would raise price by £2.50 |
https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097 |
Ha ha https://www.alliancepharmaceuticals.com/ |
We know you love APH but please stop pushing it everywhere! |
Bought some APH today |
"So far everything is going very well" always make me think of a guy falling off the roof of a big tower when he's half way down |
For the last six months,AZN has traded fairly predictably between £100 to £110. |
UBS cuts AstraZeneca to 'sell' (buy) - price target 10,700 (13,000) pence
or..
Morgan Stanley raises AstraZeneca price target to 13,400 (12,900) pence - 'overweight' |
are they buying APH ?? |
Jefferies cuts AstraZeneca to 'hold' (buy) - price target 11,000 (12,500) pence |
January 02, 2024 at 08:55 am
JP Morgan analyst James Gordon maintains his Buy rating on the stock. The target price remains unchanged at GBX 13000. |
On the FTSE 100, AstraZeneca was down 0.3%.
The Cambridge-based pharmaceutical firm said its and Sanofi’s long-acting monoclonal antibody treatment Beyfortus has been approved in China for the prevention of respiratory syncytial virus lower respiratory tract infection in neonates and infants.
AstraZeneca said the approval by China’s National Medical Products Administration is based on three ‘pivotal’ late-stage clinical trials and an ‘extensive’ local clinical development programme. It is anticipated to be available during the upcoming 2024/25 RSV season.
Beyfortus was approved in the EU in October 2022 and received approval by the US Food & Drug Administration in July 2023 following the unanimous recommendation by the Antimicrobial Drugs Advisory Committee in June 2023.
AstraZeneca said regulatory applications are currently under review in Japan and ‘several other countries’. |
Great RNS!! should see at least 10700 today and that is still under the 200 DMA. |
A Astra Covid vaccine is causing serious illness in some cases. Is this bad news a cause for concern?, anybody know? |
Hopefully a better year for the share price in 2024. |
Telegraph tip
Questor Wealth Preserver: as one of our holdings looks likely to be taken over, we are replacing it with a high-quality pharmaceutical stock
Article: |
Non Exec director buy
487 at £101.8956 |
9976 in, seems a good time short bet to me?
11K? |
Was expecting they would be taking over LumiraDx LMDX after partnership deal
hxxps://www.pharmashots.com/16262/lumiradx-collaborates-with-astrazeneca-and-everton-to-establish
Turns out it may be Roche RHHBY |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
